Comprehensive study of hexarhenium cluster complex Na4[{Re6Te8}(CN)6] - In terms of a new promising luminescent and X-ray contrast agent.
Octahedral rhenium cluster complexes may have considerable potential as therapeutic and diagnostic drugs due to their luminescent and X-ray contrast properties, as well as their ability to generate singlet oxygen upon photoirradiation. However, their potential biological effects and toxicity in vitro and in vivo are rather far from being understood. Thus, the aim of our research was to study cytotoxicity, intracellular localization and cellular uptake/elimination kinetics in vitro, biodistribution and acute intravenous toxicity in vivo of a complex Na4[{Re6Te8}(CN)6] as the promising compound for biomedical application. The results have demonstrated that the complex penetrates through cell membranes with the maximum accumulation in cells in 24h of incubation and have low toxic effects in vitro and in vivo. The median lethal dose (LD50) of intravenously administrated Na4[{Re6Te8}(CN)6] is equal to 1082±83mg/kg. These findings will be useful for future development of cluster-based agents for different biomedical applications.
Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russian Federation; Scientific Institute of Clinical and Experimental Lymрhology, Novosibirsk, Russian Federation; Novosibirsk State University, Novosibirsk, Russian Federation.
Anna A
AA
Krasilnikova
Scientific Institute of Clinical and Experimental Lymрhology, Novosibirsk, Russian Federation.
Anastasiya O
AO
Solovieva
Nikolaev Institute of Inorganic Chemistry SB RAS, Novosibirsk, Russian Federation.
Anton A
AA
Ivanov
Scientific Institute of Clinical and Experimental Lymрhology, Novosibirsk, Russian Federation.
Kristina E
KE
Trifonova
Scientific Institute of Clinical and Experimental Lymрhology, Novosibirsk, Russian Federation; Novosibirsk State University, Novosibirsk, Russian Federation.
Tatiana N
TN
Pozmogova
Nikolaev Institute of Inorganic Chemistry SB RAS, Novosibirsk, Russian Federation.
Alphiya R
AR
Tsygankova
Novosibirsk State University, Novosibirsk, Russian Federation; Nikolaev Institute of Inorganic Chemistry SB RAS, Novosibirsk, Russian Federation.
Anton I
AI
Smolentsev
Meshalkin Novosibirsk Research Institute of Blood Circulation Pathology, Novosibirsk, Russian Federation.
Evgeniy I
EI
Kretov
Meshalkin Novosibirsk Research Institute of Blood Circulation Pathology, Novosibirsk, Russian Federation.
David S
DS
Sergeevichev
Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russian Federation; Novosibirsk State University, Novosibirsk, Russian Federation; Nikolaev Institute of Inorganic Chemistry SB RAS, Novosibirsk, Russian Federation. Electronic address: shtopy@niic.nsc.ru.
Michael A
MA
Shestopalov
Novosibirsk State University, Novosibirsk, Russian Federation; Nikolaev Institute of Inorganic Chemistry SB RAS, Novosibirsk, Russian Federation.
Yuri V
YV
Mironov
Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russian Federation.
Alexander M
AM
Shestopalov
Scientific Institute of Clinical and Experimental Lymрhology, Novosibirsk, Russian Federation.
Alexander F
AF
Poveshchenko
Novosibirsk State University, Novosibirsk, Russian Federation.
Lidiya V
LV
Shestopalova
D003287:Contrast Media; D006801:Humans; D049449:Luminescence; D012211:Rhenium; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured; D014965:X-Rays
D003287:Contrast Media; D012211:Rhenium
Acute intravenous toxicity; Angiography; Intracellular localization; Tellurocyanide octahedral rhenium cluster complex; X-ray contrast agent